How to buy Monopar Therapeutics stock

Monopar Therapeutics Inc is a biotechnology business based in the US. Monopar Therapeutics shares (MNPR) are listed on the NASDAQ and all prices are listed in US Dollars. Monopar Therapeutics employs 6 staff and has a market cap (total outstanding shares value) of USD$84.2 million.

How to buy shares in Monopar Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Monopar Therapeutics. Find the stock by name or ticker symbol: MNPR. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Monopar Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Monopar Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Monopar Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Our top pick for

Beginners

Robinhood

Our top pick for

Building a portfolio

Sofi Invest

Our top pick for

Advanced traders

Interactive Brokers

How we chose our top picks

We evaluate stock trading platforms against a range of metrics that include fees, ease of use, available securities and advanced tools to meet specific investor needs. We encourage you to compare stock platforms to find one that's best for your particular budget and goals.

• Our pick for beginners. We chose Robinhood for this category because it offers commission-free trading and is easy to use. You can search for stocks by company name, and the mobile app is clean and intuitive to use.
• Our pick for building a portfolio. We chose SoFi for this category because it offers both commission-free stocks and a free robo-advisor. That means you can open an active investing account to pick and choose companies you want to invest in, and open a robo-advisor account to help you build a portfolio and manage how much risk you take on.
• Our pick for active traders. We picked Interactive Brokers for this category because it offers advanced tools and low fees for active investors and pros. The simpler IBKR Lite platform is aimed at less-active investors, but all users older than 21 must meet a $20,000 liquid net worth requirement for a cash account.

What's in this guide?

1. MNPR shares summary
2. Compare share dealing platforms
3. Is MNPR stock a buy or sell?
4. Stock performance over time
5. Can I short MNPR shares?
6. Monopar Therapeutics's financials
7. Does Monopar Therapeutics pay a dividend?
8. Other common questions

Monopar Therapeutics share price

Use our graph to track the performance of MNPR stocks over time.

Monopar Therapeutics shares at a glance

• Key figures

Information last updated 2021-02-23.

52-week range	USD$4.28 - USD$10.55
50-day moving average	USD$7.6152
200-day moving average	USD$5.9165
Wall St. target price	USD$35
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-0.4054

Buy Monopar Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Sort by:

Name	Product	Stock trade fee	Asset types	Option trade fee	Annual fee	Signup bonus
Robinhood		$0	Stocks, Options, ETFs, Gold/Commodities	$0	0%	Free stock (chosen randomly with a value anywhere between $2.50 and $200) Sign up using the "go to site" link	Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.	Go to site More Info		loading Fetching your data...
Interactive Brokers		$0	Stocks, Bonds, Options	$0 + $0.65/contract, $1 minimum	0%	N/A	IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.	Go to site More Info		loading Fetching your data...
Tastyworks		$0	Stocks, Options, Cryptocurrency	Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg Futures: $2.50/contract to open, $0 to close	0%	Get 100 shares of stock (worth $1 to $6 a share) Open and fund a new cash or margin account with $2,000+	Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.	Go to site More Info		loading Fetching your data...
Moomoo		$0 for US stocks	Stocks, Options, ETFs	$0		N/A	Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.	Go to site More Info		loading Fetching your data...
TradeStation		$0	Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency	$0 + $0.50/contract		$50 Deposit qualifying assets of $5,000+	A platform built for all kinds of traders and all styles of trading	Go to site More Info		loading Fetching your data...

loading

Compare up to 4 providers

Clear selection

Compare

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Monopar Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Monopar Therapeutics Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Shorting Monopar Therapeutics shares

There are currently 23,595 Monopar Therapeutics shares held short by investors – that's known as Monopar Therapeutics's "short interest". This figure is 1.8% down from 24,031 last month.

There are a few different ways that this level of interest in shorting Monopar Therapeutics shares can be evaluated.

Monopar Therapeutics's "short interest ratio" (SIR)

Monopar Therapeutics's "short interest ratio" (SIR) is the quantity of Monopar Therapeutics shares currently shorted divided by the average quantity of Monopar Therapeutics shares traded daily (recently around 138794.11764706). Monopar Therapeutics's SIR currently stands at 0.17. In other words for every 100,000 Monopar Therapeutics shares traded daily on the market, roughly 170 shares are currently held short.

However Monopar Therapeutics's short interest can also be evaluated against the total number of Monopar Therapeutics shares, or, against the total number of tradable Monopar Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Monopar Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Monopar Therapeutics shares in existence, roughly 0 shares are currently held short) or 0.0073% of the tradable shares (for every 100,000 tradable Monopar Therapeutics shares, roughly 7 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Monopar Therapeutics.

Find out more about how you can short Monopar Therapeutics stock.

Monopar Therapeutics overview

Monopar Therapeutics Inc., a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase III for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and MNPR-101, a humanized monoclonal antibody for treating advanced solid cancers. The company has a collaboration Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19. Monopar Therapeutics Inc. was founded in 2014 and is headquartered in Wilmette, Illinois.

Frequently asked questions

• What percentage of Monopar Therapeutics is owned by insiders or institutions?

  Currently 73.457% of Monopar Therapeutics shares are held by insiders and 0.682% by institutions.

• How many people work for Monopar Therapeutics?

  Latest data suggests 6 work at Monopar Therapeutics.

• When does the fiscal year end for Monopar Therapeutics?

  Monopar Therapeutics's fiscal year ends in December.

• Where is Monopar Therapeutics based?

  Monopar Therapeutics's address is: 1000 Skokie Boulevard, Wilmette, IL, United States, 60091

• What is Monopar Therapeutics's ISIN number?

  Monopar Therapeutics's international securities identification number is: US61023L1089

• What is Monopar Therapeutics's CUSIP number?

  Monopar Therapeutics's Committee on Uniform Securities Identification Procedures number is: 61023L108